PMID- 26301332
OWN - NLM
STAT- MEDLINE
DCOM- 20160919
LR  - 20220318
IS  - 2291-2797 (Electronic)
IS  - 2291-2789 (Print)
IS  - 2291-2789 (Linking)
VI  - 29
IP  - 8
DP  - 2015 Nov-Dec
TI  - A 14-day course of triple therapy is superior to a 10-day course for the 
      eradication of Helicobacter pylori: A Canadian study conducted in a 'real world' 
      setting.
PG  - e7-10
LID - 17013 [pii]
AB  - BACKGROUND: Successful Helicobacter pylori eradication with the traditional 
      seven-day course of proton pump inhibitor (PPI) triple therapy is declining. 
      Prolonging therapy to either 10 or 14 days is associated with better eradications 
      rates. OBJECTIVE: To compare the effectiveness of 14-day course of triple therapy 
      versus a 10-day course in the treatment of H pylori in Canada. METHODS: 
      Consecutive treatment-naive patients with clinical indications for H pylori 
      eradication underwent either a 10-day course or a 14-day course of traditional 
      PPI triple therapy depending on the date of the office visit (an odd date 
      received the 10-day course, whereas an even date received the 14-day treatment). 
      H pylori eradication was ascertained via urea breath test or gastric biopsies 
      performed >/=4 weeks after completion of therapy. Analyses were by both intention 
      to treat and per-protocol. RESULTS: A total of 83 patients were included in the 
      study (31 in the 10-day group and 52 in the 14-day group). In the 
      intention-to-treat analysis, eradication rates were 82.7% (95% CI 70% to 92%) 
      versus 45.2% (95% CI 27% to 64%), favouring the 14-day treatment (P<0.001). 
      Similarly, in the per-protocol analysis, eradication rates were 91.5% (95% CI 80% 
      to 98%) versus 63.6% (95% CI 41% to 83%), favouring the 14-day arm (P=0.01). 
      Adverse events and compliance were not significantly different between the two 
      groups. CONCLUSION: A 14-day course of standard PPI triple therapy was superior 
      to a shorter-duration therapy and should be included as a first-line regimen for 
      H pylori eradication in Canada. The 10-day course of treatment did not achieve an 
      acceptable eradication rate and should no longer be used in this country.
FAU - Chen, Yen-I
AU  - Chen YI
FAU - Fallone, Carlo A
AU  - Fallone CA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
DEP - 20150824
PL  - Egypt
TA  - Can J Gastroenterol Hepatol
JT  - Canadian journal of gastroenterology & hepatology
JID - 101623613
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Aged
MH  - Amoxicillin/*administration & dosage
MH  - Anti-Bacterial Agents/*administration & dosage
MH  - Breath Tests
MH  - Canada
MH  - Clarithromycin/*administration & dosage
MH  - Drug Therapy, Combination
MH  - Female
MH  - Helicobacter Infections/*drug therapy
MH  - Helicobacter pylori
MH  - Humans
MH  - Lansoprazole/*administration & dosage
MH  - Male
MH  - Middle Aged
MH  - Proton Pump Inhibitors/*administration & dosage
MH  - Stomach/microbiology
PMC - PMC4699606
EDAT- 2015/08/25 06:00
MHDA- 2016/09/20 06:00
PMCR- 2016/05/01
CRDT- 2015/08/25 06:00
PHST- 2015/08/25 06:00 [entrez]
PHST- 2015/08/25 06:00 [pubmed]
PHST- 2016/09/20 06:00 [medline]
PHST- 2016/05/01 00:00 [pmc-release]
AID - 17013 [pii]
AID - cjgh-29-e7 [pii]
AID - 10.1155/2015/659390 [doi]
PST - ppublish
SO  - Can J Gastroenterol Hepatol. 2015 Nov-Dec;29(8):e7-10. doi: 10.1155/2015/659390. 
      Epub 2015 Aug 24.